Terms: = Ovarian cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889
35 results:
1. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract] [Full Text] [Related]
2. Prediction of the survival of patients with advanced-stage ovarian cancer patients undergoing interval cytoreduction with the use of computed tomography reevaluation after neoadjuvant chemotherapy.
Li JY; Wang R
J Obstet Gynaecol Res; 2023 Nov; 49(11):2700-2710. PubMed ID: 37528642
[TBL] [Abstract] [Full Text] [Related]
3. Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases.
Duchnowska R; Supernat AM; Pęksa R; Łukasiewicz M; Stokowy T; Ronen R; Dutkowski J; Umińska M; Iżycka-Świeszewska E; Kowalczyk A; Och W; Rucińska M; Olszewski WP; Mandat T; Jarosz B; Bieńkowski M; Biernat W; Jassem J
Sci Rep; 2022 Nov; 12(1):20537. PubMed ID: 36446793
[TBL] [Abstract] [Full Text] [Related]
4. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013.
Nagase S; Ohta T; Takahashi F; Yamagami W; Yaegashi N;
J Obstet Gynaecol Res; 2022 Mar; 48(3):541-552. PubMed ID: 35026864
[TBL] [Abstract] [Full Text] [Related]
5. Building the What Comes Next Cohort for
Dossa F; Metcalfe K; Sutradhar R; Little T; Eisen A; Chun K; Meschino WS; Velsher L; Ellis JL; Baxter NN
CMAJ Open; 2021; 9(3):E874-E885. PubMed ID: 34870614
[TBL] [Abstract] [Full Text] [Related]
6. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract] [Full Text] [Related]
7. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic cancer.
Goldstein JB; Zhao L; Wang X; Ghelman Y; Overman MJ; Javle MM; Shroff RT; Varadhachary GR; Wolff RA; McAllister F; Futreal A; Fogelman DR
Clin Cancer Res; 2020 Mar; 26(6):1385-1394. PubMed ID: 31871297
[TBL] [Abstract] [Full Text] [Related]
8. CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling.
Codilupi T; Taube D; Naegeli H
BMC Cancer; 2019 Nov; 19(1):1042. PubMed ID: 31690264
[TBL] [Abstract] [Full Text] [Related]
9. ERCC1-xpf deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
[TBL] [Abstract] [Full Text] [Related]
10. The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.
Zhao Z; Zhang A; Zhao Y; Xiang J; Yu D; Liang Z; Xu C; Zhang Q; Li J; Duan P
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29669843
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients.
Zhao M; Li S; Zhou L; Shen Q; Zhu H; Zhu X
Life Sci; 2018 Feb; 194():34-39. PubMed ID: 29247747
[TBL] [Abstract] [Full Text] [Related]
12. The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
Lee WP; Lan KH; Li CP; Chao Y; Hou MC; Lin HC; Lee SD
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):917-928. PubMed ID: 28088627
[TBL] [Abstract] [Full Text] [Related]
13. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
[TBL] [Abstract] [Full Text] [Related]
14. Hyper IgM Syndrome: a Report from the USIDNET Registry.
Leven EA; Maffucci P; Ochs HD; Scholl PR; Buckley RH; Fuleihan RL; Geha RS; Cunningham CK; Bonilla FA; Conley ME; Ferdman RM; Hernandez-Trujillo V; Puck JM; Sullivan K; Secord EA; Ramesh M; Cunningham-Rundles C
J Clin Immunol; 2016 Jul; 36(5):490-501. PubMed ID: 27189378
[TBL] [Abstract] [Full Text] [Related]
15. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M
Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of the ERCC1-xpf structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract] [Full Text] [Related]
17. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of rare variants in the new fanconi anemia gene ercc4 (FANCQ) as familial breast/ovarian cancer susceptibility alleles.
Osorio A; Bogliolo M; Fernández V; Barroso A; de la Hoya M; Caldés T; Lasa A; Ramón y Cajal T; Santamariña M; Vega A; Quiles F; Lázaro C; Díez O; Fernández D; González-Sarmiento R; Durán M; Piqueras JF; Marín M; Pujol R; Surrallés J; Benítez J
Hum Mutat; 2013 Dec; 34(12):1615-8. PubMed ID: 24027083
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of ERCC1/xpf genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
[TBL] [Abstract] [Full Text] [Related]
20. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract] [Full Text] [Related]
[Next]
